recombinant influenza hemagglutinin
Phase 1Biologic
recombinant influenza hemagglutinin is one of 26 biologic programs targeting Influenza. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
recombinant influenza hemagglutinin
VVaxine Pty Ltd
Phase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Diphtheria-Tetanus-Acellular Pertussis Vaccine
CanSino Biologics Inc.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- VVaxine Pty Ltd